XML 25 R12.htm IDEA: XBRL DOCUMENT
v3.20.2

EARNINGS PER COMMON SHARE | 6 Months Ended
--- | ---
Jun. 30, 2020
Earnings Per Share [Abstract] |
EARNINGS PER COMMON SHARE | EARNINGS PER COMMON SHARE The computation of basic and diluted earnings per common share for the three and six months ended June 30, 2020 and 2019 were as follows:
Basic Earnings Per Common Share Computation |  | Three Months Ended |  |  |  | Six Months Ended |  |
(in millions, except per share amounts) |  | 2020 |  | 2019 |  | 2020 |  | 2019
Net (loss) income attributable to Dentsply Sirona |  | $ | (95.4) |  |  | $ | 36.4 |  |  | $ | (235.3) |  |  | $ | 75.6 |
Weighted average common shares outstanding |  | 218.7 |  |  | 224.2 |  |  | 219.8 |  |  | 223.7 |
(Loss) earnings per common share - basic |  | $ | (0.44) |  |  | $ | 0.16 |  |  | $ | (1.07) |  |  | $ | 0.34 |
Diluted Earnings Per Common Share Computation |  | Three Months Ended |  |  |  | Six Months Ended |  |
(in millions, except per share amounts) |  | 2020 |  | 2019 |  | 2020 |  | 2019
Net (loss) income attributable to Dentsply Sirona |  | $ | (95.4) |  |  | $ | 36.4 |  |  | $ | (235.3) |  |  | $ | 75.6 |
Weighted average common shares outstanding |  | 218.7 |  |  | 224.2 |  |  | 219.8 |  |  | 223.7 |
Incremental weighted average shares from assumed exercise of dilutive options from stock-based compensation awards |  | — |  |  | 1.5 |  |  | — |  |  | 1.6 |
Total weighted average diluted shares outstanding |  | 218.7 |  |  | 225.7 |  |  | 219.8 |  |  | 225.3 |
(Loss) earnings per common share - diluted |  | $ | (0.44) |  |  | $ | 0.16 |  |  | $ | (1.07) |  |  | $ | 0.34 |
The calculation of weighted average diluted common shares outstanding excluded 0.7 million and 1.0 million of potentially diluted common shares because the Company reported a net loss for the three and six months ended June 30, 2020, respectively. Stock options and RSUs of 4.2 million and 3.1 million equivalent shares of common stock that were outstanding during the three and six months ended June 30, 2020 were excluded because their effect would be antidilutive. There were 3.1 million and 3.6 million antidilutive equivalent shares of common stock outstanding during the three and six months ended June 30, 2019. On March 9, 2020, the Company entered into an accelerated share repurchase agreement with a financial institution pursuant to an Accelerated Share Repurchase Transaction (“ASR Agreement") to purchase $140.0 million of shares of the Company's common stock. Pursuant to the terms of the ASR Agreement, the Company delivered $140.0 million cash to a financial institution and received an initial delivery of 2.7 million shares of the Company’s common stock on March 9, 2020 based on a closing market price of $42.12 per share and the applicable contractual discount. The Company received the remaining 1.0 million shares on May 12, 2020. The average price per share for the total shares purchased under the ASR Agreement was $38.88 per share.

X
- References No definition available. + Details
Name: | us-gaap_EarningsPerShareAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for earnings per share. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -URI http://asc.fasb.org/topic&trid=2144383 + Details
Name: | us-gaap_EarningsPerShareTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration